Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jul;34(7):e23270.
doi: 10.1002/jcla.23270. Epub 2020 May 4.

The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B

Li-Kun Zhong  1 , Guo Zhang  1 , Shuang-Yan Luo  1 , Wu Yin  2 , Huai-Yu Song  1
Affiliations

The value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B

Li-Kun Zhong et al. J Clin Lab Anal. 2020 Jul.

Abstract

Objective: To investigate the value of platelet count in evaluating the degree of liver fibrosis in patients with chronic hepatitis B (CHB).

Methods: A total of 158 CHB patients who underwent liver biopsy in our hospital were included, and the clinical characteristics of these patients were retrospectively analyzed. The diagnostic values of platelet count, aspartate aminotransferase-to-platelet ratio index (APRI), and the fibrosis index based on four factors (FIB-4) for significant fibrosis (F ≥ 2) and early cirrhosis (F = 4) stages in CHB patients were assessed by the use of receiver operating characteristic (ROC) analysis.

Results: The median (F0: 221.0; F1: 210.0; F2: 188.0; F3: 171.0; and F4: 155.5) and mean rank (F0: 120.4; F1: 100.1; F2: 82.2; F3: 67.9; and F4: 49.5) of platelet count decreased along the aggravation of fibrosis (F0-F4). The areas under the ROC curve for the platelet count in diagnosis of significant fibrosis stage was 0.70, which had no significant difference with FIB-4 (0.73) and APRI (0.68) in diagnostic efficacy (P = .428). The areas under the ROC curve of platelet count in diagnosis of early cirrhosis were 0.72, which had no significant difference with FIB-4 (0.76) and APRI (0.68) (P = .094).

Conclusion: The platelet count, as a simple and non-invasive index, could evaluate the degree of liver fibrosis in CHB individuals. At the same time, the diagnostic efficiency of platelet count to evaluate the significant liver fibrosis and early cirrhosis is comparable to FIB-4 and APRI.

Keywords: chronic hepatitis B; liver cirrhosis; liver fibrosis; platelet count.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Area under ROC curves of PLT, APRI, and FIB‐4 for the diagnosis of hepatic fibrosis (F ≥ 2; n = 158). APRI, aspartate aminotransferase‐to‐platelet ratio index; FIB‐4, the fibrosis index based on four factors; PLT, platelet count
Figure 2
Figure 2
Area under ROC curves of PLT, APRI, and FIB‐4 for the diagnosis of liver cirrhosis (F = 4; n = 158). APRI, aspartate aminotransferase‐to‐platelet ratio index; FIB‐4, the fibrosis index based on four factors; PLT, platelet count
See this image and copyright information in PMC

References

    1. WHO Organization . Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. Geneva: WHO Organization; 2015. - PubMed
    1. Ganem D, Prince AM. Hepatitis B virus infection–natural history and clinical consequences. N Engl J Med. 2004;350(11):1118‐1129. - PubMed
    1. Kim KH, Shin HJ, Kim K, et al. Hepatitis B virus X protein induces hepatic steatosis via transcriptional activation of SREBP1 and PPARgamma. Gastroenterology. 2007;132(5):1955‐1967. - PubMed
    1. Xiao G, Yang J, Yan L. Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis‐4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: a systemic review and meta‐analysis. Hepatology. 2015;61(1):292‐302. - PubMed
    1. Kim WR, Berg T, Asselah T, et al. Evaluation of APRI and FIB‐4 scoring systems for non‐invasive assessment of hepatic fibrosis in chronic hepatitis B patients. J Hepatol. 2016;64(4):773‐780. - PubMed

Substances